- PR Newswire•yesterday
PRINCETON, N.J., March 27, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2016. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are extremely pleased with the positive results from the Phase 2 study of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer.
- PR Newswire•13 days ago
Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference
PRINCETON, N.J., March 15, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer of Soligenix will present preclinical and clinical results on the use of dusquetide (SGX94) in the treatment of emerging and antibiotic resistant infectious diseases at Superbugs & Superdrugs – A Focus on Antibacterials. The conference is being held in London March 20-21, 2017. Innate Defense Regulators: Agnostic Therapy For Antibiotic Resistant Disease – "Supercharging existing and new antibiotic therapies," presented by Dr. Oreola Donini, Chief Scientific Officer of Soligenix, on March 20, 2017 at 1:20 pm local time. Conference details are available here.
- Zacks Small Cap Research•15 days ago
On March 10, 2017, Soligenix (SNGX) announced that it will present results from its ricin toxin vaccine (RiVax™) development program on March 15 at the Society of Toxicology 56th Annual Meeting. The poster is titled: Verification of Lethal Doses of Inhaled Ricin in Rhesus Macaques to Support Vaccine Development. RiVax™ is the Company's proprietary vaccine candidate for the prevention of exposure to ricin toxin that utilizes a unique antigen that is completely devoid of the toxic activity of ricin.
SNGX : Summary for Soligenix, Inc. - Yahoo Finance
Soligenix, Inc. (SNGX)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.68 x 200|
|Day's Range||2.28 - 2.47|
|52 Week Range||1.90 - 9.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|